Ponvory (ponesimod) coverage for multiple sclerosis
Defines clinical coverage and prior authorization criteria for Ponvory (ponesimod) for treatment of relapsing forms of multiple sclerosis for Cigna-administered health benefit plans.
Added a definition for documentation.
Added a specialist prescribing requirement.
Added criteria for patients currently receiving Ponvory for ≥ 1 year.
Removed Employer Plans preferred product requirements (previously present).
Added preferred product requirements for Ponvory on Employer Plans, effective 7/1/2025.
Ocrevus Zunovo was added to the Appendix.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.